search
Back to results

Using mHealth to Optimize Pharmacotherapy Regimens

Primary Purpose

Schizophrenia, First-Episode Psychosis

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
mHealth Intervention
Sponsored by
New York State Psychiatric Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Schizophrenia focused on measuring mHealth, Schizophrenia, EMA

Eligibility Criteria

16 Years - 30 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female OnTrackNY participants, ages 16 to 30, of any race/ethnicity
  • Able and willing to give informed consent and participate in the intervention
  • Participating in OnTrackNY for less than 1 year because this group may be more in need of medication adjustments and will be less likely to graduate from the program before 6 months of participation.

Exclusion Criteria:

  • Suicidal at baseline with C-SSRS score 4 or 5.
  • PANSS baseline score of 5 (moderately severe) or greater on the Conceptual Disorganization item (P2)

Sites / Locations

  • Bestself Behavioral Health, Inc.
  • Washington Heights Community Service
  • Lenox Hill Hospital
  • Institute for Family Health

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

mHealth intervention group

Treatment as Usual group

Arm Description

participants in the mHealth Group will download the app on to their smartphone and complete ecological momentary assessments on 3 consecutive weekdays every 2 weeks for 6 months.

participants will undergo their routine treatment.

Outcomes

Primary Outcome Measures

change of Treatment Satisfaction Questionnaire for Medication (TQSM) from baseline to 6 months
The TSQM assesses client satisfaction with medication. It comprises 14 items across four domains focusing on effectiveness (3 items), side effects (5 items), convenience (3 items), and global satisfaction (3 items) of the medication over the previous 2-3 weeks, or since the patient's last use. With the exception of item 4 (presence of side effects; yes or no), all items have five or seven responses, scored from one (least satisfied) to five or seven (most satisfied).The 7-item scales had a non-neutral midpoint, such that there were more positive response options than negative response options, to allow for precise information to be obtained at the upper end of the score distribution. Item scores are summed to give four domain scores, which are in turn transformed to a scale of 0-100. Item 4 was not included for scoring. If an item score is missing and half of the items in the domain are complete, domain scores may be imputed from the person-specific mean score of completed items.
change of Client Satisfaction Questionnaire (CSQ-8) from baseline to 6 months
8-item easily scored and administered measurement that is designed to measure client satisfaction with services. The overall score is produced by summing all item responses. Scores range from 8 to 32, with higher values indicating higher satisfaction.

Secondary Outcome Measures

Full Information

First Posted
January 22, 2020
Last Updated
January 23, 2023
Sponsor
New York State Psychiatric Institute
Collaborators
Northwell Health, Early Treatment Program at Lenox Hill, The Institute for Family Health Center for Counseling at Walton, New York State Psychiatric Institute, Washington Heights Community Service, BestSelf Behavioral Health
search

1. Study Identification

Unique Protocol Identification Number
NCT04248517
Brief Title
Using mHealth to Optimize Pharmacotherapy Regimens
Official Title
Using mHealth to Optimize Pharmacotherapy Regimens
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Completed
Study Start Date
October 9, 2020 (Actual)
Primary Completion Date
December 31, 2022 (Actual)
Study Completion Date
January 20, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
New York State Psychiatric Institute
Collaborators
Northwell Health, Early Treatment Program at Lenox Hill, The Institute for Family Health Center for Counseling at Walton, New York State Psychiatric Institute, Washington Heights Community Service, BestSelf Behavioral Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This project will use a smartphone technology to improve medication prescribing for individuals with FEP. We will collect real-time symptom and functioning data via smartphones to provide prescribers and other clinical team members with clinically relevant and time-sensitive information that will inform and promote shared decision making (SDM) and personalized interventions. The result will be a time-sensitive, data-driven, collaborative process to optimize medication regimens in order to maximize benefits, minimize harms, and promote adherence.
Detailed Description
Comprehensive early treatment of individuals experiencing schizophrenia has the potential to alter the course of illness and improve long-term outcomes. Psychotropic medications are a critical component of early treatment strategies. First-episode psychosis (FEP) is a critical time to optimize prescribing but evidence suggests that prescribing for this population is suboptimal. A contributing factor to these difficulties is thought to be the lack of accurate information about the effects of medications on symptoms, their side effects, as well as their behavioral, cognitive, and emotional correlates. At medication management appointments, prescribers typically rely on patients' recollection of how they were doing over periods of weeks. Such retrospective assessments are problematic as they are vulnerable to the influence of memory difficulties, cognitive biases including recency effects and frequency illusions, and reframing. Recent advances in smartphone technologies (mobile Health; mHealth) may help to overcome many of the limitations of retrospective assessments. This pilot study will be a collaboration with OnTrackNY, an innovative coordinated specialty care (CSC) program for individuals aged 16-30 who are experiencing FEP. OnTrackNY originated as part of the NIMH Recovery After an Initial Schizophrenia Episode (RAISE) Implementation and Evaluatoin Study. The initial phase of this project will use input from stakeholders including patients, front-line providers, clinical leaders, and members of the research team to adapt and refine the mHealth intervention to improve feasibility and clinical utility. A pilot study at 3 OnTrackNY sites will then examine its feasibility and effectiveness by comparing the management and outcomes of 60 patients randomly assigned to the mHealth application or usual care.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia, First-Episode Psychosis
Keywords
mHealth, Schizophrenia, EMA

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective cohort with comparison group
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
23 (Actual)

8. Arms, Groups, and Interventions

Arm Title
mHealth intervention group
Arm Type
Experimental
Arm Description
participants in the mHealth Group will download the app on to their smartphone and complete ecological momentary assessments on 3 consecutive weekdays every 2 weeks for 6 months.
Arm Title
Treatment as Usual group
Arm Type
No Intervention
Arm Description
participants will undergo their routine treatment.
Intervention Type
Other
Intervention Name(s)
mHealth Intervention
Intervention Description
Participants will download the app onto their smartphone and complete ecological momentary assessements
Primary Outcome Measure Information:
Title
change of Treatment Satisfaction Questionnaire for Medication (TQSM) from baseline to 6 months
Description
The TSQM assesses client satisfaction with medication. It comprises 14 items across four domains focusing on effectiveness (3 items), side effects (5 items), convenience (3 items), and global satisfaction (3 items) of the medication over the previous 2-3 weeks, or since the patient's last use. With the exception of item 4 (presence of side effects; yes or no), all items have five or seven responses, scored from one (least satisfied) to five or seven (most satisfied).The 7-item scales had a non-neutral midpoint, such that there were more positive response options than negative response options, to allow for precise information to be obtained at the upper end of the score distribution. Item scores are summed to give four domain scores, which are in turn transformed to a scale of 0-100. Item 4 was not included for scoring. If an item score is missing and half of the items in the domain are complete, domain scores may be imputed from the person-specific mean score of completed items.
Time Frame
baseline to 6 months
Title
change of Client Satisfaction Questionnaire (CSQ-8) from baseline to 6 months
Description
8-item easily scored and administered measurement that is designed to measure client satisfaction with services. The overall score is produced by summing all item responses. Scores range from 8 to 32, with higher values indicating higher satisfaction.
Time Frame
baseline to 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female OnTrackNY participants, ages 16 to 30, of any race/ethnicity Able and willing to give informed consent and participate in the intervention Participating in OnTrackNY for less than 1 year because this group may be more in need of medication adjustments and will be less likely to graduate from the program before 6 months of participation. Exclusion Criteria: Suicidal at baseline with C-SSRS score 4 or 5. PANSS baseline score of 5 (moderately severe) or greater on the Conceptual Disorganization item (P2)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Scott Stroup, MD, MPH
Organizational Affiliation
New York State Psychiatric Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Bestself Behavioral Health, Inc.
City
Buffalo
State/Province
New York
ZIP/Postal Code
14202
Country
United States
Facility Name
Washington Heights Community Service
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
Lenox Hill Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Facility Name
Institute for Family Health
City
New York
State/Province
New York
ZIP/Postal Code
10453
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Raw data will be made available for research to investigators working under a Federal Wide Assurance who meet security measures and data use agreement criteria associated with public repositories including the National Database for Clinical Trials related to Mental Illness (NDCT). Data will include baseline demographic data, and baseline and post raw data derived from functioning and symptom measures.
IPD Sharing Time Frame
A list of all data expected to be collected in the project will be submitted within 6 months of award. Subsequently, descriptive and raw data will be submitted on a semi-annual basis. Unpublished de-identified data will be submitted prior to study completion and will be shared within one year after project completion, or when the data are published, whichever is earlier.
IPD Sharing Access Criteria
Data in NIH repositories may be accessed through the NIH Data Access Committee which reviews data access and submission requests.
Citations:
PubMed Identifier
36331539
Citation
Stefancic A, Rogers RT, Styke S, Xu X, Buchsbaum R, Nossel I, Cabassa LJ, Stroup TS, Kimhy D. Development of the First Episode Digital Monitoring mHealth Intervention for People With Early Psychosis: Qualitative Interview Study With Clinicians. JMIR Ment Health. 2022 Nov 4;9(11):e41482. doi: 10.2196/41482.
Results Reference
derived

Learn more about this trial

Using mHealth to Optimize Pharmacotherapy Regimens

We'll reach out to this number within 24 hrs